Serum metabolomics as a novel diagnostic approach for pancreatic cancer

Shin Nishiumi, Masakazu Shinohara, Atsuki Ikeda, Tomoo Yoshie, Naoya Hatano, Saori Kakuyama, Shigeto Mizuno, Tsuyoshi Sanuki, Hiromu Kutsumi, Eiichiro Fukusaki, Takeshi Azuma, Tadaomi Takenawa, Masaru Yoshida

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Pancreatic cancer is one of the leading causes of cancer-related death, and there is currently little hope of a cure because there are no effective biomarkers for its early detection. Therefore, the search for novel biomarkers that would allow the early detection of pancreatic cancer is ongoing. In this study, the differences between the metabolomes of pancreatic cancer patients with Stage III, Stage IVa, or Stage IVb disease (n = 20) and healthy volunteers (n = 9) were evaluated by metabolomics, which is the endpoint of the Omics cascade and therefore the last step in the cascade before the phenotype. In our experimental conditions using gas chromatography mass spectrometry (GC/MS), a total of 60 metabolites were detected in serum, and the levels of 18 of the 60 metabolites were significantly changed in pancreatic cancer patients compared with those in healthy volunteers. Then, Principal Component Analysis (PCA), which is a basic form of Multiple Classification Analysis, was performed, and the PCA scores plots based on the 60 metabolites highlighted the metabolomic differences between the pancreatic cancer patients and healthy volunteers. The differences between different stages of pancreatic cancer were also assessed by Partial Least Squares Discriminant Analysis (PLS-DA), which is one of Multiple Classification Analysis, and we found that it was possible to discriminate among the Stage III, Stage IVa, and Stage IVb groups. In addition, values of the 9 metabolites in 1 Stage I pancreatic cancer patient were similar to those obtained from the Stage III, Stage IVa, and Stage IVb pancreatic cancer patients. Our findings will aid the discovery of novel biomarkers that allow the early detection of pancreatic cancer by metabolomic approaches.

Original languageEnglish
Pages (from-to)518-528
Number of pages11
JournalMetabolomics
Volume6
Issue number4
DOIs
Publication statusPublished - Dec 1 2010
Externally publishedYes

Fingerprint

Metabolomics
Metabolites
Pancreatic Neoplasms
Biomarkers
Serum
Principal component analysis
Healthy Volunteers
Discriminant analysis
Gas chromatography
Principal Component Analysis
Mass spectrometry
Early Detection of Cancer
Metabolome
Discriminant Analysis
Least-Squares Analysis
Gas Chromatography-Mass Spectrometry
Phenotype

Keywords

  • GC/MS
  • Metabolomics
  • Pancreatic cancer
  • PCA
  • PLS-DA

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Clinical Biochemistry

Cite this

Nishiumi, S., Shinohara, M., Ikeda, A., Yoshie, T., Hatano, N., Kakuyama, S., ... Yoshida, M. (2010). Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics, 6(4), 518-528. https://doi.org/10.1007/s11306-010-0224-9

Serum metabolomics as a novel diagnostic approach for pancreatic cancer. / Nishiumi, Shin; Shinohara, Masakazu; Ikeda, Atsuki; Yoshie, Tomoo; Hatano, Naoya; Kakuyama, Saori; Mizuno, Shigeto; Sanuki, Tsuyoshi; Kutsumi, Hiromu; Fukusaki, Eiichiro; Azuma, Takeshi; Takenawa, Tadaomi; Yoshida, Masaru.

In: Metabolomics, Vol. 6, No. 4, 01.12.2010, p. 518-528.

Research output: Contribution to journalArticle

Nishiumi, S, Shinohara, M, Ikeda, A, Yoshie, T, Hatano, N, Kakuyama, S, Mizuno, S, Sanuki, T, Kutsumi, H, Fukusaki, E, Azuma, T, Takenawa, T & Yoshida, M 2010, 'Serum metabolomics as a novel diagnostic approach for pancreatic cancer', Metabolomics, vol. 6, no. 4, pp. 518-528. https://doi.org/10.1007/s11306-010-0224-9
Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, Kakuyama S et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010 Dec 1;6(4):518-528. https://doi.org/10.1007/s11306-010-0224-9
Nishiumi, Shin ; Shinohara, Masakazu ; Ikeda, Atsuki ; Yoshie, Tomoo ; Hatano, Naoya ; Kakuyama, Saori ; Mizuno, Shigeto ; Sanuki, Tsuyoshi ; Kutsumi, Hiromu ; Fukusaki, Eiichiro ; Azuma, Takeshi ; Takenawa, Tadaomi ; Yoshida, Masaru. / Serum metabolomics as a novel diagnostic approach for pancreatic cancer. In: Metabolomics. 2010 ; Vol. 6, No. 4. pp. 518-528.
@article{dc18b62200d94e28bac41803a95afc62,
title = "Serum metabolomics as a novel diagnostic approach for pancreatic cancer",
abstract = "Pancreatic cancer is one of the leading causes of cancer-related death, and there is currently little hope of a cure because there are no effective biomarkers for its early detection. Therefore, the search for novel biomarkers that would allow the early detection of pancreatic cancer is ongoing. In this study, the differences between the metabolomes of pancreatic cancer patients with Stage III, Stage IVa, or Stage IVb disease (n = 20) and healthy volunteers (n = 9) were evaluated by metabolomics, which is the endpoint of the Omics cascade and therefore the last step in the cascade before the phenotype. In our experimental conditions using gas chromatography mass spectrometry (GC/MS), a total of 60 metabolites were detected in serum, and the levels of 18 of the 60 metabolites were significantly changed in pancreatic cancer patients compared with those in healthy volunteers. Then, Principal Component Analysis (PCA), which is a basic form of Multiple Classification Analysis, was performed, and the PCA scores plots based on the 60 metabolites highlighted the metabolomic differences between the pancreatic cancer patients and healthy volunteers. The differences between different stages of pancreatic cancer were also assessed by Partial Least Squares Discriminant Analysis (PLS-DA), which is one of Multiple Classification Analysis, and we found that it was possible to discriminate among the Stage III, Stage IVa, and Stage IVb groups. In addition, values of the 9 metabolites in 1 Stage I pancreatic cancer patient were similar to those obtained from the Stage III, Stage IVa, and Stage IVb pancreatic cancer patients. Our findings will aid the discovery of novel biomarkers that allow the early detection of pancreatic cancer by metabolomic approaches.",
keywords = "GC/MS, Metabolomics, Pancreatic cancer, PCA, PLS-DA",
author = "Shin Nishiumi and Masakazu Shinohara and Atsuki Ikeda and Tomoo Yoshie and Naoya Hatano and Saori Kakuyama and Shigeto Mizuno and Tsuyoshi Sanuki and Hiromu Kutsumi and Eiichiro Fukusaki and Takeshi Azuma and Tadaomi Takenawa and Masaru Yoshida",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/s11306-010-0224-9",
language = "English",
volume = "6",
pages = "518--528",
journal = "Metabolomics",
issn = "1573-3882",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Serum metabolomics as a novel diagnostic approach for pancreatic cancer

AU - Nishiumi, Shin

AU - Shinohara, Masakazu

AU - Ikeda, Atsuki

AU - Yoshie, Tomoo

AU - Hatano, Naoya

AU - Kakuyama, Saori

AU - Mizuno, Shigeto

AU - Sanuki, Tsuyoshi

AU - Kutsumi, Hiromu

AU - Fukusaki, Eiichiro

AU - Azuma, Takeshi

AU - Takenawa, Tadaomi

AU - Yoshida, Masaru

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Pancreatic cancer is one of the leading causes of cancer-related death, and there is currently little hope of a cure because there are no effective biomarkers for its early detection. Therefore, the search for novel biomarkers that would allow the early detection of pancreatic cancer is ongoing. In this study, the differences between the metabolomes of pancreatic cancer patients with Stage III, Stage IVa, or Stage IVb disease (n = 20) and healthy volunteers (n = 9) were evaluated by metabolomics, which is the endpoint of the Omics cascade and therefore the last step in the cascade before the phenotype. In our experimental conditions using gas chromatography mass spectrometry (GC/MS), a total of 60 metabolites were detected in serum, and the levels of 18 of the 60 metabolites were significantly changed in pancreatic cancer patients compared with those in healthy volunteers. Then, Principal Component Analysis (PCA), which is a basic form of Multiple Classification Analysis, was performed, and the PCA scores plots based on the 60 metabolites highlighted the metabolomic differences between the pancreatic cancer patients and healthy volunteers. The differences between different stages of pancreatic cancer were also assessed by Partial Least Squares Discriminant Analysis (PLS-DA), which is one of Multiple Classification Analysis, and we found that it was possible to discriminate among the Stage III, Stage IVa, and Stage IVb groups. In addition, values of the 9 metabolites in 1 Stage I pancreatic cancer patient were similar to those obtained from the Stage III, Stage IVa, and Stage IVb pancreatic cancer patients. Our findings will aid the discovery of novel biomarkers that allow the early detection of pancreatic cancer by metabolomic approaches.

AB - Pancreatic cancer is one of the leading causes of cancer-related death, and there is currently little hope of a cure because there are no effective biomarkers for its early detection. Therefore, the search for novel biomarkers that would allow the early detection of pancreatic cancer is ongoing. In this study, the differences between the metabolomes of pancreatic cancer patients with Stage III, Stage IVa, or Stage IVb disease (n = 20) and healthy volunteers (n = 9) were evaluated by metabolomics, which is the endpoint of the Omics cascade and therefore the last step in the cascade before the phenotype. In our experimental conditions using gas chromatography mass spectrometry (GC/MS), a total of 60 metabolites were detected in serum, and the levels of 18 of the 60 metabolites were significantly changed in pancreatic cancer patients compared with those in healthy volunteers. Then, Principal Component Analysis (PCA), which is a basic form of Multiple Classification Analysis, was performed, and the PCA scores plots based on the 60 metabolites highlighted the metabolomic differences between the pancreatic cancer patients and healthy volunteers. The differences between different stages of pancreatic cancer were also assessed by Partial Least Squares Discriminant Analysis (PLS-DA), which is one of Multiple Classification Analysis, and we found that it was possible to discriminate among the Stage III, Stage IVa, and Stage IVb groups. In addition, values of the 9 metabolites in 1 Stage I pancreatic cancer patient were similar to those obtained from the Stage III, Stage IVa, and Stage IVb pancreatic cancer patients. Our findings will aid the discovery of novel biomarkers that allow the early detection of pancreatic cancer by metabolomic approaches.

KW - GC/MS

KW - Metabolomics

KW - Pancreatic cancer

KW - PCA

KW - PLS-DA

UR - http://www.scopus.com/inward/record.url?scp=78649334462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649334462&partnerID=8YFLogxK

U2 - 10.1007/s11306-010-0224-9

DO - 10.1007/s11306-010-0224-9

M3 - Article

AN - SCOPUS:78649334462

VL - 6

SP - 518

EP - 528

JO - Metabolomics

JF - Metabolomics

SN - 1573-3882

IS - 4

ER -